Thalidomide in Treating Patients With Myelodysplastic Syndrome

Sponsor

National Cancer Institute (NCI) (NIH)

Overall Status

Completed

CT.gov ID

NCT00015990

Collaborator

(none)

Enrollment

Location

Arm

Study Details

Study Description

Brief Summary

Phase II trial to study the effectiveness of thalidomide in treating patients who have myelodysplastic syndrome. Thalidomide may improve the immune system's ability to fight myelodysplastic syndrome

Condition or Disease	Intervention/Treatment	Phase
Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndromes Previously Treated Myelodysplastic Syndromes Refractory Anemia Refractory Anemia With Excess Blasts Refractory Anemia With Excess Blasts in Transformation Refractory Anemia With Ringed Sideroblasts Secondary Myelodysplastic Syndromes	Drug: thalidomide Other: laboratory biomarker analysis	Phase 2

Detailed Description

OBJECTIVES:

Determine whether thalidomide improves cytopenias in patients with myelodysplastic syndromes.
Determine the toxicity of this regimen in these patients. III. Determine whether this regimen down regulates the peripheral blood levels of tumor necrosis factor alpha, interferon gamma, and interleukin-12 and whether these changes correlate with clinical response in these patients.
Determine whether this regimen alters the peripheral blood T-cell subset distribution and whether these changes correlate with clinical response in these patients.
Determine the effect of this regimen on bone marrow microvessel density and whether these effects correlate with clinical response in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to prognosis (favorable vs unfavorable). (Favorable stratum closed to accrual 12/28/01)

Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months for 1 year and then annually for 4 years.

PROJECTED ACCRUAL: A total of 20-58 patients (10-29 per stratum) will be accrued for this study within 20 months. (Favorable stratum closed to accrual 12/28/01)

Study Design

Study Type:

Interventional

Actual Enrollment :

29 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Study of Thalidomide in the Treatment of Myelodysplastic Syndromes in Adults: A Clinical and Biologic Study

Study Start Date :

Apr 1, 2001

Actual Primary Completion Date :

Feb 1, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (thalidomide) Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.	Drug: thalidomide Given orally Other Names: Kevadon Synovir THAL Thalomid Other: laboratory biomarker analysis Correlative studies

Arm

Intervention/Treatment

Experimental: Treatment (thalidomide)

Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.

Drug: thalidomide

Given orally

Other Names:

Kevadon

Synovir

THAL

Thalomid

Other: laboratory biomarker analysis

Correlative studies

Outcome Measures

Primary Outcome Measures

Confirmed response defined as complete hematologic response (CHR) or partial response (PR) or hematological improvement (HI) on 2 consecutive evaluations in terms of proportion of successes measured using criteria reported by Cheson et al [Up to 3 months]
Ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
Incidence and severity of toxicities, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0 [Up to 5 years]

Secondary Outcome Measures

Survival time [Time from registration to death due to any cause, assessed up to 5 years]
Estimated using the method of Kaplan-Meier.
Time to disease progression [Time from registration to documentation of disease progression, assessed up to 5 years]
Estimated using the method of Kaplan-Meier.
Duration of response measured using criteria reported by Cheson et al [Date at which the patient's objective status is first noted to be either a CHR or PR to the date progression is documented, assessed up to 5 years]
Time to treatment failure [Time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Pre-transfusion hemoglobin =< 10 g/dL
Pre-transfusion platelet count =< 50,000/μL
Absolute neutrophil count < 1000/μL
Total bilirubin ≤ 1.5 x UNL
Alkaline phosphatase ≤ 3 x UNL
AST ≤ 3 x UNL
Creatinine ≤ 1.5 x UNL
A diagnosis of MDS as demonstrated in the bone marrow; any subtypes are eligible including:
Refractory anemia (cytopenia)
Refractory anemia with ringed sideroblasts
Chronic myelomonocytic leukemia
Refractory anemia with excess blasts
Refractory anemia with excess blasts in transformation
Unclassified MDS
Patients with refractory anemia with excess blasts in transformation who are not candidates for (or who decline) induction chemotherapy are eligible; those patients who were candidates for (and accepted) induction chemotherapy should have failed at least 1 chemotherapy regimen prior to entry
Patients who are candidates for marrow transplantation should have this option discussed prior to study entry

Exclusion Criteria:

Any of the following as this regimen may be harmful to a developing fetus or nursing child:
Pregnant women
Nursing women
Women of childbearing potential or their sexual partners who are unwilling to employ 2 adequate methods of contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.)
Peripheral neuropathy (by history or clinical exam)
Concomitant therapy ≤ 30 days for myelodysplastic syndrome with any specific agent including chemotherapy, corticosteroids and/or growth factors (i.e. erythropoietin, G-CSF, GM-CSF, thrombopoietic agent); patients on chronic low-dose corticosteriods (< 20 mg/d) for reasons other than MDS are allowed
Uncontrolled infections